Breast Cancer

Latest News

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com
Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

AJMC
Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com
Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com
Same-Day Breast Imaging Gaps Reveal Health Care Disparities

February 18th 2025

Pink ribbon for breast cancer | Image Credit: Andrey Popov - stock.adobe.com
Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

February 17th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

Woman hugging sister with cancer | Image Credit: Pixel-Shot - stock.adobe.com
February 21st 2024

Study Finds Sisters of Women With High Breast Cancer Risk Share Common Factors

Cameron Santoro
Sisters of women with high breast cancer risk share similar risk factors, including high polygenic scores, benign breast disease history, and denser breast tissue.
Douglas K. Marks, MD | Image credit: NYU Langone Health
February 20th 2024

Getting to Know Dr Doug Marks, Oncology Clinical Trialist

Maggie L. Shaw
Douglas K. Marks, MD, is a breast medical oncologist and director of the Clinical Trials Office, Perlmutter Cancer Center, NYU Langone Hospital—Long Island, as well as associate professor in the Department of Medicine at NYU Grossman Long Island School of Medicine. As a phase 1 clinical trialist, he sees both patients with breast cancer and those who are looking to receive innovative treatments for their early-stage disease.
Illustration of woman getting mammogram | Image Credit: forestgraphic - stock.adobe.com
February 16th 2024

Swedish Study Links False-Positive Mammograms to Elevated Breast Cancer Risk

Cameron Santoro
Swedish women with prior false-positive mammograms, particularly those aged 60 to 75 with prior biopsies and low density, show elevated breast cancer risk, necessitating closer monitoring and better screening.
3 women with breast cancer of different ethnicities | Image Credit: Mary Long - stock.adobe.com
February 14th 2024

Cultural Influences, Surgical Decision-Making Approaches for Non-Caucasian Women With Breast Cancer

Cameron Santoro
Non-Caucasian patients with breast cancer face common influences in surgical decision-making due to fear, misinformation, cultural factors, and power dynamics, highlighting the need for patient-centered surgical decision-making.
Cancer survivor practicing yoga | Image Credit: Halfpoint - stock.adobe.com
February 9th 2024

Physical Activity, Aerobic Exercise Programs Show Promise in Combating CRCI in Breast Cancer Survivors

Cameron Santoro
Research suggests moderate to vigorous physical activity may help improve cognitive function in breast cancer survivors who have undergone chemotherapy and developed cancer-related cognitive impairment (CRCI).
ICYMI: Highlights From SABCS 2023
December 31st 2023

ICYMI: Highlights From SABCS 2023

Maggie L. Shaw
This year’s top content from the annual San Antonino Breast Cancer Symposium (SABCS) is concentrated in 3 areas: health equity, benign breast disease, and fertility preservation following diagnosis.
Image depicting breast cancer
December 27th 2023

Neoadjuvant/Adjuvant Pembrolizumab Regimen Continues to Show EFS Benefit in High-Risk Early TNBC

Gina Mauro
The 5-year event-free survival EFS) rate was 81.3% with neoadjuvant pembrolizumab/chemotherapy followed by adjuvant pembrolizumab compared with 72.3% in those who received placebo/chemotherapy plus placebo.
Graphic repping 2023's top breast cancer articles
December 24th 2023

Top 5 Most-Read Breast Cancer Articles of 2023

Maggie L. Shaw
In breast cancer coverage this year, topline results from the phase 3 NATALEE trial made waves in March, with our other most-read content in the space covering an expanded indication for abemaciclib, revised screening recommendations, a new potential treatment to reduce radiation exposure, and the benefits of diet and exercise on patient outcomes.
Breast cancer | Image Credit: Crystal Light - stock.adobe.com
December 22nd 2023

Neoadjuvant KN026 Plus Docetaxel Demonstrate Early Activity in HER2+ Breast Cancer

Ryan Scott
A combination of KN026, a novel bispecific antibody, and docetaxel elicited responses with an acceptable toxicity profile when administered as neoadjuvant treatment in patients with HER2-positive (HER2+) early or locally advanced breast cancer.
group of patinets holding a brast cancer awareness ribbon | Image credit: Rawpixel.com - stock.adobe.com
December 18th 2023

Higher Survival Rates Found in Male Hispanic, API Patients With Early Breast Cancer

Brooke McCormick
These findings suggest that addressing socioeconomic disparities and inequities that impact access to health care and services may help improve survival outcomes across racial/ethnic groups of male patients with early breast cancer.
Breast cancer | Image Credit:Science RF - stock.adobe.com
December 15th 2023

Subcutaneous Trastuzumab Induces Immune Function in HER2+ Breast Cancer

Sabrina Serani
Trastuzumab administered subcutaneously delivered unique immunomodulation effects vs intravenous trastuzumab in patients with treatment-naïve HER2-positive (HER2+) breast cancer
Top 5 graphic representing conference highlights
December 11th 2023

ICYMI: Highlights From the ACCC Fall National Oncology Conference

Maggie L. Shaw
This year’s top content from the fall meeting of the Association of Community Cancer Centers (ACCC) highlights both treatment gains made through innovative referral, screening, and assistance initiatives and the ongoing need to improve health equity and research inclusivity.
Representation of breast cancer | Image Credit: Giovanni Cancemi - stock.adobe.com
December 5th 2023

Trastuzumab Biosimilar Gets Go Ahead in EU for HER2+ Breast and Metastatic Gastric Cancers

Kyle Doherty
EG12014, a biosimilar of the anti-HER2 monoclonal antibody trastuzumab, has received a marketing authorization from the European Commission for use in the European Union (EU) for the treatment of patients with HER2-positive (HER2+) breast and metastatic gastric cancer; these are the same indications that trastuzumab holds in the European Union.
Image representing breast cancer | Image credit: vectorfusionart - stock.adobe.com
November 28th 2023

Counseling, Support Areas of Urgent Need Among Mothers With Breast Cancer

Maggie L. Shaw
Data are scarce on the impact that breast cancer among mothers has on their children and their emotional development due to parenting stress and maternal depression.
FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations
November 20th 2023

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

Chris Ryan
The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alteration, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.
Breast Cancer | Image Credit: Axel Kock - stock.adobe.com
November 16th 2023

Lack of Vitamin D May Increase Chemo-Induced Neuropathy Risk in Breast Cancer

Rina Lokaj
Investigators note that prospective research is needed to confirm the efficacy of vitamin D supplements in preventing chemotherapy-induced peripheral neuropathy in patients with breast cancer.
A female doctor sits at her desk and talks to a female patient while looking at her mammogram. Braest cancer prevention | Image Credit: lordn - stock.adobe.com
November 13th 2023

Call to Action Issued for Education on Lesser-Known Breast Cancer Symptoms

Maggie L. Shaw
Some of these symptoms include breast puckering, nipple discharge, and retracted nipple.
Women Value Different Aspects of Care in Breast Reconstruction
November 10th 2023

Women Value Different Aspects of Care in Breast Reconstruction

Julia Bonavitacola
Women of varying backgrounds, educational levels, and marriage status opted for different types of breast reconstruction based on different values.
FDA on textured paper | Image Credit: Araki Illustrations - stock.adobe.com
November 6th 2023

Rhenium Obisbemeda for Breast Cancer, Leptomeningeal Metastases Receives ODD From FDA

Jordyn Sava
Rhenium (186Re) obisbemeda (Plus Therapeutics) shows potential to address the unmet need of new treatment options for patients with breast cancer and leptomeningeal metastases and will continue to be evaluated in the ReSPECT-LM program. The orphan drug designation (ODD) was granted on November 3.
SDOH Social Determinants Of Health Concept - The meeting at the white office table | Image Credit: STOATPHOTO - stock.adobe.com
November 4th 2023

Wide Variation Seen in County-Level Breast Cancer Mortality Linked to SDOH

Maggie L. Shaw
Data from 2176 US counties link obesity and higher breast cancer mortality, while also showing varying degrees of association between mortality and access to healthy lifestyle options per social determinants of health (SDOH).
Afreen Idris Shariff, MD, MBBS, Duke Cancer Institute
November 2nd 2023

Dr Afreen Idris Shariff: Cancer Care Can Transform Through e-Consults

Pearl Steinzor Maggie L. Shaw
Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
Kristine Slam, MD< FACP, Central Ohio Surgical Associates
October 29th 2023

Dr Kristine Slam: Patients With Breast Cancer Must Advocate for Themselves

Maggie L. Shaw
Kristine Slam, MD, FACP, discusses the importance of genetic testing in male patients with breast cancer and why it’s important that all patients with breast cancer advocate for themselves.
Mike Koroscik, MBA, MHA, Allina Health and the Allina Health Cancer Institute
October 26th 2023

Allina Health’s Mike Koroscik on Revolutionizing Early Cancer Detection Through Technology

Pearl Steinzor Maggie L. Shaw
Through the integration of a population health reimbursement model in 2020, Allina Health Cancer Institute was able to implement expanded screening initiatives through the use of artificial intelligence and precision medicine, according to Mike Koroscik, MBA, MHA, vice president of oncology, Allina Health.
Image of women with breast cancer - Vasyl - stock.adobe.com.jpe.jpg
October 25th 2023

Racial, Ethnic Disparities Seen in Breast Cancer Survival, Even Among Clinical Trial Participants

Pearl Steinzor
It is critical to understand the role race and ethnicity play in survival for patients with early-stage breast cancer (eBC), as well as explore potential interventions to close these gaps.
Woman undergoing mammography | Image credit: Peakstock - stock.adobe.com
October 21st 2023

Opt-In vs Opt-Out Patient Outreach Programs Yield Similar Mammography Completion Rates

Skylar Jeremias
No differences in mammography completion were observed between an automated opt-out vs an opt-in patient outreach program for breast cancer screening, according to a randomized controlled trial. However, differences in administration burden between programs could lead clinics to prefer one over the other.
Breast cancer with lymphatics | Image Credit: Axel Kock - stock.adobe.com
October 19th 2023

Low Adherence to Endocrine Therapy Highlights Urgent Need in the Breast Cancer Space

Maggie L. Shaw
Study investigators note their meta-analysis may be the first to demonstrate the importance of interventions to support adherence to adjuvant endocrine therapy for breast cancer.
Kristine Sllam, MD, FACP, Central Ohio Surgical Associates
October 16th 2023

Dr Kristine Slam: In Breast Cancer, Patient Values and Treatment Goals May Differ

Maggie L. Shaw
Kristine Slam, MD, FACP, Central Ohio Surgical Associates, addresses the importance of involving patients in decisions regarding their goals for treatment, emphasizing that this involvement is critical to uncover what they value, as well as their short- and long-term goals for treatment.
Scott Gray, cofounder and CEO, Clincierge | Image Credit: Clincierge
October 11th 2023

Contributor: Advancing Breast Cancer Treatment—The Role of Clinical Trials and the Path Ahead

Scott Gray
Clinical studies have transformed how breast cancer is prevented, identified, and treated. Successful clinical trials improve patient outcomes, so trial administrators must ensure participants receive appropriate support at trial enrollment.
What We’re Reading: Robotic Mastectomies; Racial Discrimination in Maternity Care
October 9th 2023

What We’re Reading: Robotic Mastectomies; Maternity Care Discrimination; Ongoing Kaiser Permanente Strike Issues

AJMC Staff
A minimally invasive procedure could revolutionize breast surgery; Black women experience the worst birthing outcomes; Kaiser Permanente health workers' concerns over labor disputes persist.
FDA on Paper Texture - Araki Illustrations - stock.adobe.com
October 6th 2023

FDA Grants Fast Track Designation to IDE161 for Select Pretreated BRCA1/2-Mutated HR+ Breast Cancer

Kristi Rosa
The FDA has granted fast track designation to IDE161 for use in adult patients with advanced or metastatic hormone receptor–positive, HER2-negative breast cancer harboring BRCA1/2 mutations who have progressed after at least 1 hormonal therapy, a CDK4/6 inhibitor, and a poly (ADP-ribose) polymerase inhibitor.
<12345678
...
13>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo